Literature DB >> 15863653

Management of multidrug-resistant tuberculosis and patients in retreatment.

J A Caminero1.   

Abstract

Retreatment of tuberculosis involves the management of entities as diverse as relapse, failure, treatment after default, and poor patient adherence to the previous treatment. The emergence of conditions for selection of resistance (failure and partial abandonment) is a matter of great concern. The development of a retreatment regimen for tuberculosis requires consideration of certain basic premises. The importance of a comprehensive and directed history of drugs taken in the past, and the limited reliability of susceptibility tests to many of these drugs, should be kept in mind. Taking this into account, and possessing a thorough knowledge of all anti-tuberculosis medications, it is possible to cure almost all patients with an appropriate retreatment regimen including a minimum of three or four drugs not previously used. Nonetheless, the treatment of these patients is so complex that it should only be carried out by experienced staff. Concern about treating tuberculosis patients with drug resistance varies greatly depending on the available resources. High-income countries should provide individual treatment regimens adapted to each patient; however, in other settings, restricted resources could justify the implementation of standardised therapeutic guidelines with second-line drugs in order to facilitate management and reduce costs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863653     DOI: 10.1183/09031936.05.00103004

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  18 in total

1.  Multidrug-resistant tuberculosis in the Czech Republic: strategy and therapeutic outcomes.

Authors:  V Bartu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-08       Impact factor: 3.267

2.  High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study.

Authors:  Carlos Acuña-Villaorduña; Irene Ayakaka; Scott Dryden-Peterson; Susan Nakubulwa; William Worodria; Nancy Reilly; Jennifer Hosford; Kevin P Fennelly; Alphonse Okwera; Edward C Jones-López
Journal:  Am J Trop Med Hyg       Date:  2015-05-04       Impact factor: 2.345

3.  Mixed Mycobacterium tuberculosis complex infections and false-negative results for rifampin resistance by GeneXpert MTB/RIF are associated with poor clinical outcomes.

Authors:  Nicola M Zetola; Sanghyuk S Shin; Kefentse A Tumedi; Keletso Moeti; Ronald Ncube; Mark Nicol; Ronald G Collman; Jeffrey D Klausner; Chawangwa Modongo
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

4.  Tuberculosis, drug resistance, and HIV/AIDS: a triple threat.

Authors:  Gerald Friedland
Journal:  Curr Infect Dis Rep       Date:  2007-05       Impact factor: 3.725

5.  European union standards for tuberculosis care.

Authors:  G B Migliori; J P Zellweger; I Abubakar; E Ibraim; J A Caminero; G De Vries; L D'Ambrosio; R Centis; G Sotgiu; O Menegale; K Kliiman; T Aksamit; D M Cirillo; M Danilovits; M Dara; K Dheda; A T Dinh-Xuan; H Kluge; C Lange; V Leimane; R Loddenkemper; L P Nicod; M C Raviglione; A Spanevello; V Ø Thomsen; M Villar; M Wanlin; J A Wedzicha; A Zumla; F Blasi; E Huitric; A Sandgren; D Manissero
Journal:  Eur Respir J       Date:  2012-04       Impact factor: 16.671

6.  Antitubercular effect of 8-[(4-Chloro phenyl) sulfonyl]-7-Hydroxy-4-Methyl-2H-chromen-2-One in guinea pigs.

Authors:  Parvati B Patel; Tejas K Patel; Seema N Baxi; Hemangini R Acharya; Chandrabhanu Tripathi
Journal:  J Pharmacol Pharmacother       Date:  2011-10

7.  Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies.

Authors:  R Prasad
Journal:  Lung India       Date:  2012-04

8.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

9.  Management of extensively drug-resistant tuberculosis in Peru: cure is possible.

Authors:  Cesar A Bonilla; Aldo Crossa; Hector O Jave; Carole D Mitnick; Ronal B Jamanca; Cesar Herrera; Luis Asencios; Alberto Mendoza; Jaime Bayona; Matteo Zignol; Ernesto Jaramillo
Journal:  PLoS One       Date:  2008-08-13       Impact factor: 3.240

10.  A simple scoring system to differentiate between relapse and re-infection in patients with recurrent melioidosis.

Authors:  Direk Limmathurotsakul; Wipada Chaowagul; Narisara Chantratita; Vanaporn Wuthiekanun; Mayurachat Biaklang; Sarinna Tumapa; Nicholas J White; Nicholas P J Day; Sharon J Peacock
Journal:  PLoS Negl Trop Dis       Date:  2008-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.